About us

At TJ Bio, we are committed to creating innovative immunotherapies for patients worldwide. As a fully integrated biotech company, we strive to lead the way in autoimmune diseases and immuno-oncology, bringing life-changing therapies from lab to patient. Our approach creates a diverse and sustainable revenue model , generating value for the Company and our shareholders in China and globally.

Formed through strategic restructuring in early 2024, TJ Bio builds upon established R&D capabilities in Shanghai and Beijing (since 2016) and manufacturing facilities in Hangzhou (since 2020). This integration has strengthened our capacity to advance our differentiated pipeline, including three near-BLA assets.
Our discovery and research engine drives a next-generation pipeline of highly innovative clinical and pre-clinical assets, focusing on bi-specific antibodies and antibody-drug conjugate for autoimmune diseases and oncology.
We operate under two key principles:
  • In China for China: Delivering innovative medicines at controlled manufacturing costs to the local market.
  • In China for Global: Partnering with global companies to develop select assets for worldwide markets.

Platform-Powered Innovation

Beijing

Hangzhou Manufacturing Facility (Headquarters)

· Drug Manufacturing Permit Holder

· GMP manufacturing + CMC & formulation labs

· Clinical & commercial production: 3x2kL expandable to 6x2kL

Shanghai R&D Center

· Research laboratory

· Clinical development

· Corporate functions

Beijing Center

· Clinical development

· Regulatory affairs

· Government affairs

Our Pipeline

Advanced and Differentiated Pipeline

Metabolic Diseases
Immuno-Oncology
Inflammatory Diseases
AssetsAreasIndicationsPre-ClinicalPhase 1Phase 2Phase 3BLAPartnershipRights
1
Near-Term Product Pipeline
Aiming for 3 product launches in 2026 and multiple BLA submissions in 2027
Best-in-Class Potential
Felzartamab CD38
Multiple Myeloma
IgA Nephropathy
PMN
BLA submitted Dec 2024
PREVAIL
PROMINENT
BTD and ODD granted (FDA)
Greater China
Eftansomatropin alfa Long-acting hGH
PGHD
BLA submitted Dec 2024
China
Efmedaglutide alfa Long-acting GLP-1
Obesity
Diabetes
BLA submitted Oct 2025
China
Plonmarlimab GM-CSF
MAS/sHLH
Gouty Arthritis
PRIME-1
BTD granted (NMPA)
PRIME-2
Global
Uliledlimab CD73
NSCLC (1L Doublet)
NSCLC (1L Triplet)
UPLIFT
SPARK
Greater China
Givastomig Claudin18.2 x 4-1BB
Gastric cancer
ODD granted (FDA)
Greater China
2
Next-Generation Pipeline
Platform-enabled IND-ready and Phase 1 assets
First-in-Class Potential
TJ-C64B BsAb
Ovarian and Gastric cancers
IND approved, Phase 1 ready
Global
TJ-RO4B BsAb
Multiple cancers
Global
TJ-L1IF BsAb
PD-1 resistant cancers
Global
TJ-MC203 TsAb
Immune reset autoimmune diseases and cancers
Global
TJ-AGC Antibody-conjugate portfolio
1L treatments for autoimmune diseases
Global
Other clinical assets including:
efineptakin alfa (a phase 2 stage, long-acting IL-7 fusion protein for treatment in multiple cancers),
izastobart (a phase 1/2 stage, C5aR1 antibody for treatment in multiple autoimmune diseases), and
TJ-L1A3 (a phase 1 stage, PD-L1 x LAG3 BsAb for treatment in multiple cancers).
Abbreviations: PGHD = Pediatric Growth Hormone Deficiency; NSCLC = Non-Small Cell Lung Cancer; MAS = Macrophage Activation Syndrome; sHLH = Secondary Hemophagocytic Lymphohistiocytosis; PMN = Primary Membranous Nephropathy; BsAb = Bi-specific Antibody; TsAb = Tri-specific Antibody; 1L = First-Line Treatment; Doublet = Uliledlimab + PD-1; Triplet = Uliledlimab + PD-1 + Chemotherapy; BTD = Breakthrough Therapy Designation; ODD = Orphan Drug Designation; BLA = Biologic License Application; IND = Investigational New Drug; NMPA = China National Medical Products Administration; FDA = US Food and Drug Administration

News Center

Learn more
Learn more